Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial
Open Access
- 1 May 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 7 (3), 418-426
- https://doi.org/10.1161/circheartfailure.113.001036
Abstract
Background—: Soluble ST2 (sST2), a biomarker related to inflammation, is associated with outcomes of patients with heart failure. In-depth analyses of the relationship among sST2, changes in sST2, and patient outcomes are reported. Methods and Results—: sST2 was measured at baseline (n=1650), 4 months (n=1345), and 12 months (n=1094) in Valsartan Heart Failure Trial. Baseline sST2 averaged 28.7±16.2 ng/mL, significantly ( P 33.2 ng/mL. Each segment of the sST2 distribution was significantly ( P P <0.001) reduced the rate of increase in sST2. Increases in sST2 for 12 months, but not decreases, were significantly associated with subsequent outcomes, independent of clinical variables, sST2, and valsartan treatment. Conclusions—: In this study, baseline sST2 was nonlinearly associated with patient outcomes but did not provide substantial prognostic information when added to a clinical prediction model that included N-terminal probrain natriuretic peptide. An increase but not decrease in sST2 was independently associated with outcomes. Additional research is needed to determine whether monitoring ST2 levels can improve patient outcomes.Keywords
This publication has 22 references indexed in Scilit:
- Multiple Biomarkers for Risk Prediction in Chronic Heart FailureCirculation: Heart Failure, 2012
- Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiologyEuropean Journal of Heart Failure, 2012
- Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failureEuropean Journal of Heart Failure, 2012
- Establishment of reference intervals for soluble ST2 from a United States populationClinica Chimica Acta; International Journal of Clinical Chemistry, 2010
- Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart FailureJournal of Cardiac Failure, 2008
- The IL-33/ST2 pathway: therapeutic target and novel biomarkerNature Reviews Drug Discovery, 2008
- Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) StudyJournal of the American College of Cardiology, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial InfarctionCirculation, 2004
- Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial InfarctionCirculation, 2002